Autonomix Medical Reports New Topline Results From First 15 Patients' 7-Day Data Highlighting Significant Impact On Treatment Of Pancreatic Cancer Pain With Maintained Pain Reduction; 79% Responder Rate Achieved With Zero Opioid Use And Quality Of Life Improvement At 7 Days Post-Procedure; Clinically Meaningful Mean Of 4.96 Or 63% Reduction Of Pain On The VAS Pain Scale Was Observed

79% responder rate achieved with zero opioid use and quality of life improvement at 7 days post-procedure

Company reaches 60% enrollment with 15 patients1 successfully enrolled; No unexpected complications or procedural-related significant adverse events

Clinically meaningful mean of 4.96 or 63% reduction of pain on the VAS pain scale was observed

THE WOODLANDS, TX, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced preliminary positive results from the first 15 patients in the Company's ongoing proof-of-concept human clinical trial (the "Trial") evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.